Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities

NCT07690579 | Recruiting

• 2 other identifiers: 255517U54CA302452
• Study Type: observational
• Target: 350
• Locations: 1 country
• Sites: 1

Brief Summary

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity. The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor. These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

Conditions

Prostate Cancer; Prostate Cancer Recurrent; Prostate Metastases

Keywords

Radical Prostatectomy

Outcome Measures

Primary Outcomes (1)

• Identification of not yet identified factors contributing to prostate cancer

  Genomic and SSDH factors will be evaluated to locate not yet identified factors that are associated with greater immune activation and prediction of unfavorable vs. favorable prostate cancer biology by race and ethnicity groups.

  Up to 2 years

Study Arms (1)

Men with prostate cancer

Participants who have planned or completed a non-investigational radical prostatectomy will be asked to complete a series of questionnaires online covering a subset of community-informed SSDH measures and individual exposures. Responses will be recorded in a secured database. . It will take about up to 2 hours to complete the surveys. There will be questions about your demographics (education level, income, employment, etc.); health care access and quality; lifestyle and behaviors. Data from your medical record about your prostate cancer and treatment will also be collected.

Other: Questionnaires; Other: Medical Record Review

Interventions

Questionnaires OTHER

Participants will receive surveys to complete online via a secure system.

Also known as: Surveys

Men with prostate cancer

Medical Record Review OTHER

Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.

Also known as: Medical Chart Review

Men with prostate cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult participants with prostate cancer with a planned RP scheduled to be performed at a University of California, San Francisco (UCSF) facility.

You may qualify if:

• Participants who have elected radical prostatectomy as prostate cancer treatment.
• Participants who have agreed to participate in the Urology Biobank.

You may not qualify if:

• Participant does not plan nor schedule a radical prostatectomy (RP) procedure.

Sponsors & Collaborators

• University of California, San Francisco: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

RECRUITING

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Matthew Cooperberg, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Kiana Washington

CONTACT

415.514.8026; Kiana.Washington@ucsf.edu

Karina Acevedo

CONTACT

415.353.7615; Karina.Acevedo@ucsf.edu

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: July 8, 2026
• Study Start: March 31, 2026
• Primary Completion (Estimated): March 31, 2028
• Study Completion (Estimated): March 31, 2028
• Last Updated: July 8, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP

Locations

US (1)